Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 11—November 2015

Role of Maternal Antibodies in Infants with Severe Diseases Related to Human Parechovirus Type 31

Yuta Aizawa, Kanako Watanabe, Tomohiro Oishi, Harunobu Hirano, Isao Hasegawa, and Akihiko SaitohComments to Author 
Author affiliations: Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan (Y. Aizawa, T. Oishi, A. Saitoh); Niigata University Graduate School of Health Sciences, Niigata (K. Watanabe); Saiseikai Niigata Daini Hospital, Niigata (H. Hirano, I. Hasegawa); University of California San Diego School of Medicine, San Diego, California, USA (A. Saitoh)

Main Article

Table 1

Numbers and rates of seropositivity to HPeV types 1, 3, and 6 in cord blood samples from healthy full-term infants, by maternal age, Niigata, Japan, September 2013–January 2014*

HPeV type
Maternal age, no. (%) samples
All ages, n = 175†
16–24 y, n = 11
25–34 y, n = 107
35–44 y, n = 57
HPeV1 113 (65) 6 (55) 75 (70) 32 (56)
HPeV3 107 (61) 11 (100) 68 (64) 28 (49)
HPeV6 125 (71) 8 (73) 69 (64) 48 (84)

*HPeV, human parechovirus. A cutoff of 1:32 was used for HPeV1, 3, and 6.
†Antibody positivity rates compared among the 3 genotypes; p = 0.12.

Main Article

1Presented in part at IDWeek, October 8–12, 2014, Philadelphia, Pennsylvania, USA.

Page created: October 16, 2015
Page updated: October 16, 2015
Page reviewed: October 16, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.